Fundamental Expertise

Immunotherapies are the next generation in the fight against cancer, often showing clincal efficacy and better safety as compared to traditional therapy. Treatment strategies have expanded from targeted approaches to T-cell therapies and immune checkpoint inhibitors.

Past Experience, e.g.:

• Development of a portfolio of immuno-oncology drugs
  Development strategy and Project Management for a portfolio of multifunctional antibodies redirecting and activating a plethora of immune cells (T-cells, macrophages, dendritic cells) from pre-clinical/First-in-man/ Phase 1-3 to market approval and launch.